Clinical aspects of circulating miRNA‐335 in breast cancer patients: A prospective study

Abstract

Background: The impact of aberrant expression of miRNAs, small noncoding RNAs of 19 to 23 nucleotide, has been reported in different types of cancer, such as breast cancer. Authors aim to investigate the role of circulating miRNA-335 as a diagnostic and prognostic marker for breast cancer.Materials and Methods: miRNA-335 expression was measured in primary breast cancer patients (n = 106), patients with benign breast lesion (n = 49) and healthy individuals as control (n = 40) using quantitative real-time polymerase chain reaction and its diagnostic efficacy, relation with clinicopathological factors, and disease-free survival (DFS) and overall survival (OS) were assessed.Results: A significant decrease in miRNA-335 expression was reported in patients with breast cancer as compared to the other two investigated groups. The positivity rate for miRNA were related to adverse clinical features of primary breast cancer as high histological grading (X 2 = 7.72, P = 0.016), presence of metastasis to lymph node (X 2 = 21.8, P < 0.001), large tumor size (X 2 = 6.41, P = 0.041), and hormonal status (P < 0.001). miRNA-335 mean rank level was significantly different among breast cancer subtypes and its level was inferior in triple negative breast cancer. Worse DFS (X 2 = 7.76, P = 0.005) and OS (X 2 = 9.3, P = 0.002) were reported with decreased miRNA-335 level. Conclusion: Assessment of circulating miRNA expression level is a promising minimal invasive marker for diagnosis and prediction of breast cancer prognosis with significant discrepancies among molecular breast cancer subtypes. K E Y W O R D S breast cancer subtypes, clinicopathological factors, diagnosis, micro-RNA, prognosis, tumor suppressor J Cell Biochem. 2019;120:8975-8982.wileyonlinelibrary.com/journal/jcb

lncRNA TTN‐AS1 facilitates proliferation, invasion, and epithelial‐mesenchymal transition of breast cancer cells by regulating miR‐139‐5p/ZEB1 axis

“…In recent years, despite continuous improvements in breast cancer diagnosis and treatment technology, the mortality rate of breast cancer patients has not significantly declined 3‐5 . Nevertheless, multiple previous studies have contributed to the identification of the clinicopathological features of breast cancer, such as histological grading, lymph node involvement, and hormone receptor status, which have helped to improve prognosis, and to assess and guide treatment 6‐8 . Malignant transformation of cancer cells occurs through a multistep process involving multifunctional programming, which is considered to be the most challenging issue in interventional therapy.…”

“…receptor status, which have helped to improve prognosis, and to assess and guide treatment. [6][7][8] Malignant transformation of cancer cells occurs through a multistep process involving multifunctional programming, which is considered to be the most challenging issue in interventional therapy.…”

A Clinical Evaluation of Circulating MiR-106a and Raf-1 as Breast Cancer Diagnostic and Prognostic Markers

“…BC has been shown to have abnormal MiRNA cluster expression, which can be both pro-tumorigenic and anti-tumorigenic. So, the use of circulating MiRNAs in breast cancer diagnosis is less invasive and efficient than traditional tissue biopsy (Yoshikawa et al, 2018;Swellam et al, 2019). The role of MiR-106a in the development of tumor malignancy is complex and controversial.…”

Addressing the Clinical Feasibility of Adopting Circulating miRNA for Breast Cancer Detection, Monitoring and Management with Artificial Intelligence and Machine Learning Platforms

“…For human epidermal growth factor receptor 2 (HER2)-positive patients, circulating miR-373 was reported to be upregulated [ 24 ] and, in another Chinese study [ 53 ], it was shown that the circulating level of miR-106a-5p and miR-20b-5p was increased in HER2-negative BC patients. In triple-negative BC (TNBC), serum miR-335 was reported to be downregulated [ 54 ], whereas serum miR-200c was upregulated [ 55 ]. Other circulating miRNAs that were upregulated in TNBC include miR-188-5p, miR-642b-3p, miR-1202, miR-1207-5p, miR-1225-5p, miR-1290, miR-3141, miR-4270 and miR-4281 [ 56 ].…”